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ABSTRACT 
The new inotropic agent pren lte 01 was admini te 





witn severe chronic heart failure. Experimental heart failure in 
anesthetized dogs was induced by two vessel coronary artery 
constriction and intravenous prenalterol (0.005-15 ug/kg/min) was 
compared to dobutamine (0.001-30 ug/kg/min) and saline. 
Significant dose-dependent increases in left ventricular dP/dt 
cardiac output and non-ischemic zone contractile force and 
significant reductions in systemic vascular resistance were present 
during infusions of both inotropic agents. High dose dobutamine 
caused greater increases in mean arterial pressure and pressure 
rate product with a trend toward greater increases in heart rate. 
However, neither inotropic agent significantly improved ischemic 
zone contractile force. Prenalterol possessed a markedly longer 




Nine patients with severe chronic heart failure (left ventricular 
ejection fraction meantSD 17+5%, cardiac index 1.7k0.4 l/min/m 
responded to intravenous prenalterol (1, 4, and 8 mg) with 
significant increases in cardiac ind6x, left ventricular ejection 
fraction and left ventricular stroke work index. Left ventricular 
filling pressure, mean right atrial pressure and pulmonary 
arteriolar resistance were significantly reduced. No significant 
differences were present among peak responses to the three doses 
employed. An inverse correlation between basal heart rate and 
increase in left ventricular ejection fraction following 
prenalterol was noted. 
2 
The mechanisms by which prenalterol causes hernodynamic improvement 
appear to include a direct inotropic effect, a reduction in left 
ventricular outflow resistance and a reduction in left and right 
ventricular filling pressure (venodilating effect). The net result 
is an upward and leftward shift of the depressed ventricular 
function curve. 
Both prenalterol and dobutamine were associated with sustained 
ventricular tachyarrhythmias in the experimental acute low output 
state and two digitalized patients with ischemic cardiornyopathy 
developed transient ventricular tachycardia after prenalterol 
administration. These findings indicated that adrenergic 
stimulants should be administered in severe ischemic states with 
careful monitoring. 
INTRODUCTION 
New advances in the pharmacological therapy of low cardiac output 
states have included the introduction of vasodilator agents and the 
introduction of catecholamine inotropic agents dopamine and 
dobutamlne. These inotropic agents, however, are restricted to 
parenteral adwlnistration and cardiac glycosides remain the only 
available oral. inotropic agents for long-term therapy of heart 
failure. Prenalterol is a new orally and parenterally effective 
catecholanine-like inotropic agent with a chemical structure 
(Figure I) airilar to isoproterenol. Prenalterol has heen shown to 
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cause relatively selective increases in myocardial contractility in 
normal experimental animals [ l ]  and human volunteers [2, 31 with 
lesser effects on heart rate and blood pressure. Limited 
information, however, is available regarding its effects in low 
cardiac output states. In order to assess the efficacy of acute 
intravenous prenalterol administration in experimental and clinical 
heart failure and to compare its effects in the acute ischemic low 
output state with those of dobutamine, the following studies were 
undertaken in a canine model of acute heart failure and in patients 
with chronic severe heart failure. 
METHODS 
I. Experimental acute ischemic heart failure 
Nineteen male mongrels weighing (mean2SEM) 18.920.7 kg (range 11.6 
to 25 kg) were anesthetized with 0.5-0.8 ml/kg intravenous 
Dial-Urethane and mechanically ventilated on room air via 
endotracheal tube by Harvard respirator with a tidal volume of 
15-25 ml/kg and a rate of 10-20 cycles/min. Respiratory settings 
were adjusted to maintain arterial pH, and PC02 within normal 
limits. Arterial pressure was monitored by carotid artery 
cannulation and a continuous infusion of 30 ml/h, physiological 
saline was administered via the external jugular vein. Following 
left fifth intercostal space thoracotomy and formation of a 
pericardial cradle, the heart was instrumented as shown in Figure 
2: Brodie-Walton open arch strain gauges were sutured into the 
myocardium of the right ventricular (RV) free wall in an area 
remote from subsequent coronary artery constriction and in the 
anterior left ventricular (LV) free wall in the distribution of the 
left anterior descending (LAD) coronary artery, which was 
subsequently rendered ischemic. Measurements of non-ischemic zone 
contractile force were obtained from the RV strain gauge and 
measurements of ischemic zone contractile force from the LV strain 
gauge. Triplicate thermodilution cardiac outputs were determined 
by Columbus Cardiac Output Computer using 2.0 ml room temperature 
saline injections in the right atrium with a pulmonary artery 
thermister. Left ventricular end-diastolic pressure (LVEDP) and 
rate of LV pressure change (LV dP/dt) were obtained from a M i l l e r  
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Figure 1. Chemical structure of prenalterol. 
LAD Constrictor 




LV Strain Gauge 
(Ischemic Area) 
Figure 2. Schematic diagram of instrumentation for experimental 
Ischemic low output state. Right atrial catheter and pulmonary 
artery thermistor for cardiac output determination are not 
illustrated. 
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Mikro-tip catheter in the LV apex. Lead I1 ECG was monitored 
throughout each experiment. Screw-type constrictors were placed 
around the left circumflex (LCX) and LAD coronary arteries for 
subsequent constriction. A Gross model 7 polygraph was used to 
record measurements. 
An acute ischemic low output state was induced by progressive 
constriction of the LAD and LCX coronary arteries with the 
mechanical constrictors until cardiac output and maximum LV dP/dt 
(Lv dP/dt ) diminished and LVEDP increased. Following baseline 
measurements in the ischemic low output state, intravenous 
prenalterol (dose range 0.005-15 ug/kg/min, n=7) or intravenous 
dobutamine (dose range 0.01-30 pg/kg/min, n=6) or  comparable 
volumes of saline (n=6) were infused for 10-30 min without 
re-equilibration between doses. 
max 
Dose effect curves (Figures 3-10) are shown for the three groups. 
Values are expressed as mean2SEM. Statistical analysis for 
dose-response curve comparisons was performed by profile analysis 
for parallelism and analysis of changes within or between groups by 
paired or unpaired t-test. Analysis was performed by a 
computerized statistical program (MIDAS, University of Michigan 
Statistical Research Laboratory). A p-value of t0.05 was 
considered significant. 
Arrhythmia analysis was performed by manual count of ectopic beats 
for the last five minutes of each infusion. Five animals 
successfully defibrillated after coronary artery constriction prior 
to drug administration are included. 
11. Chronic heart failure in patients 
Nine patients with chronic, severe low output heart failure were 
studied. Age ranged from 48-70 years with mean2SD 5927 years. 
Five patients were male and four were female. The cause of heart 
failure was ischemic in six patients, idiopathic in two patients 
and alcoholic in one patient. Each patient had symptoms of heart 
failure for at least three months prior to study; all patients 
except one were in New York Heart Association Functional Class I11 
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Fiqure 3. Effect of prenalterol and dobutamine on heart rate. 
Neither inotropic agent significantly increased heart rate compared 
to saline controls. Dobutarnine tended to cause greater increases 
than prenalterol (p<O. lO) .  (Reprinted with permission from J 
Cardiovasc Pharmacol 3:896-905, 1981.) 
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Fiqure 4. Effect of prenalterol and dobutamine on mean arterial 
pressure. Dobutarnine caused significant elevations compared to 
saline controls ( p < 0 . 0 2 ) ;  prenalterol caused no change. 
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Figure 5. Effects of prenalterol and dobutamine on pressure rate 
product. Dobutamine caused significant elevations compared to 
saline controls ( p < 0 . 0 3 )  and prenalterol (p<0.03). No significant 
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LOG DOSE (pg/kg/min) 
Figure b. Effect of prenalterol and dobutamine on cardiac output 
Compared to saline controls, cardiac: output was significantly 
greater with both prenalterol (p<0.02) and dobutamine (p<O.Ol). At 
maximal dose, dobutamine caused a greater increase in cardiac 
output than prenalterol. (Reprinted with permission from J 
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Figure 7. Effect of prenalterol and dobutamine on left ventricular 
dP/d t Increases resulted with both prenalterol (p<O. 03) and 
dobutamine (p<O.OOl) compared to saline controls. (Reprinted with 
permission from J Cardiovasc Pharmacol 3: 896-905, 1981. ) 
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Basal -2.0 -1.5 -1.0 -0.5 0 0.5 1.0 1.5 
LOG DOSE (lg/kq/rnin) 
Figure 8. Effect of prenalterol and dobutamine on non-ischemic 
zone contractile force. Increases resulted with both prenalterol 
(p<O.O3) and dobutamine (p<0.005) compared to saline controls. 
(Reprinted with permission from J Cardiovasc Pharmacol 3: 896-905, 
1981. ) 270 
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Figure 9. Effect of prenalterol and dobutamine on ischemic zone 
contractile force. No significant changes resulted after 
prenalterol (p>0.25) or dobutamine (p>0.4) compared to saline 
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Figure 10. Effects of prenalterol and dobutamine on total systemic 
vascular resistance. A significant reduction occurred after 
prenalterol (p<0.03) compared to saline controls. Dobutamine 
caused a significant reduction in mean total systemic vascular 
resistance (p<O.OOl) compared to saline controls without changing 
profile parallelism significantly (p>0.15). (Reprinted with 
permission from J Cardiovasc: Pharmacol 3:896-905, 1981.) 
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or IV, and the remaining patient was in Functional Class 11. All 
patients had received chronic diuretic therapy and seven had 
received vasodilator therapy for persistent heart failure symptoms 
despite digitalis and diuretics. Five of the nine patients were 
chronically digitalized with oral digoxin in doses of 0.125 or 0.25 
mg daily, with serum digoxin levels obtained within six days of 
study ranging from 0.26 to 1.05 ng/ml (mean 0.74 ng/ml). Patients 
were studied in the post-absorptive state at least 24 hours after 
discontinuation of all vasodilator therapy and at least four hours 
after administration of all other cardiovascular medications. Two 
patients received antiarrhythmic therapy (dlsopyrami.de 100 mg 
orally four times daily and quinidine sulfate 200 mg orally four 
times daily) at the time of the investigation. 
Hemodynamic data were obtained from a triple lumen thermodilution 
flow directed pulmonary artery catheter inserted through an 
antecubital vein and from a peripheral arterial catheter (7 
patients) or blood pressure cuff (2 patients). In addition, left 
ventricular ejection fraction (LVEF)  was obtained by radionuclide 
ventriculography employing 10-20 mCi of technetium 99m for in v i v o  
red cell labelling. Equilibrium gated cardiac blood pool Imaging 
was performed in the modified left anterior oblique position with a 
gamma camera. All studies were obtained in the supine position. 
Directly measured hernodynamic parameters included systemic arterial 
pressure, right atrial pressure, pulmonary artery pressure, 
pulmonary artery wedge pressure used as an estimate of left 
ventricular filling pressure ( L V F P ) ,  cardiac output (thermodilution 
technique in 8 patients, indocyanine green dye curves in 1 
patient), and radionuclide LVEF. Standard hemodynamic formulae 
were used for derived parameters. An Electronics for Medicine VR12 
recorder was used to record measurements. 
Intravenous prenalterol was administered in doses of 1, 4, and 8 mg 
at 30 min intervals by infusion pump into a peripheral vein and 
hemodynamic measurements were obtained at 10 min and 25 min after 1 
and 4 mg and 10, 25, and 55 min after 8 ma. Peak hernodynamic: 
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Figure 11. Effect of prenalterol on heart rate in patients. 
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Figure 12. Effect of prenalterol on mean arterial pressure in 
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13. Effect of prenalterol on cardiac index 
significant increase (p<0.02)  occurred. 
INDIVIDUAL 




Figure 14. Effect of prenalterol on left ventricular filling 














Figure 15. Effect of prenalterol on left ventricular ejection 
fraction (LVEF) in patients. A significant increase (p<O.Ol) 
occurred. In one patient there was no response. 
--I- 25 











*p < .01 
PRENALTEROL 
Figure 16. Effect of prenalterol on mean right atrial pressure in 
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Figure 17. Correlation in patients between increase in left 
ventricular ejection fraction (LVEF)  with prenalterol and baseline 
heart rate prior to drug administration. A significant inverse 
correlation was present ( r  = -0 .89 ,  ~ ( 0 . 0 1 ) .  
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Figure 18. Net effect of prenalterol on left ventricular stroke 
work index (LVSWI) plo'tted against left ventricular filling 
pressure (LVFP) in patients. Values represent mean before (open 
circle) and after (arrow) prenalterol. Normal values are 
represented by dotted lines. 
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Arrhythmia analysis was obtained from continuous ECG (Holter) 
monitoring for at least 8 hours prior to prenalterol 
administration, as well as during and several hours after drug 
administration. 
Statistical analysis was performed by t-test for paired data, 
comparing control measurements and peak effect. Values are 
expressed as mean2SD. 
RESULTS 
I. Experimental acute ischemic heart failure 
An acute ischemic low output state was present after two vessel 
coronary artery constriction, with significant decreases in cardiac 
output (from 2.320.2 to 1.720.1 l/min), LV dP/dt 
to 1395260 mm Hg/s), ischemic zone contractile force (from 9627 to 
5827 g), non-ischemic zone contractile force (from 3825 to 34+5 g) 
and mean arterial pressure (from 9524 to 9023 mm Hg) and 
significant increases in LVEDP (from 721 to 1722 mm Hg) and total 
peripheral resistance (from 34612234 to 44702300 dyn*~*cm-~). 
(from 1654258 max 
Dose-response curve analysis demonstrates that both intravenous 
prenalterol and dobutamine cause significant dose-dependent 
increases in cardiac output (Figure 61, LV dP/dt (Figure 7) and 
non-ischemic zone contractile force (Figure 8) compared to saline 
controls, as well as a significant dose-dependent decrease in 
systemic vascular resistance (Figure 10). However, ischemic zone 
contractile force did not change significantly after either 
inotropic agent compared to saline controls (Figure 9). Increases 
in mean arterial pressure were significantly greater during 
dobutamine infusion (but not prenalterol infusion) than in control 
animals (Figure 4). Dobutamine tended to cause greater increases 
in heart rate at higher doses than saline (Figure 3) but this 
difference did not achieve statistical significance. Prenalterol 
caused no significant changes in heart rate. The greater increase 
in heart rate associated with dobutamine, however, largely accounts 
for the significantly higher cardiac output during high dose 
max 
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dobutamine infusion, as stroke volume was not different in the two 
groups of animals treated with inotropic agents (p>0.22, not 
graphea). Pressure rate product, an Index of myocardial oxygen 
consumption [ 4 ] ,  was calculated by multiplying systolic arterial 
pressure by heart rate, divided by 100.  As shown in Figure 5, 
dobutamine caused significantly greater increases than either 
saline or prenalterol. LVEDP did not change significantly after 
either inotropic agent. 
Arrhythmia analysis revealed that neither dobutamine nor 
prenalterol increased the number of isolated ectopic beats. Both 
inotropic agents, however, caused sustained ventricular 
tachyarrhythmias. One animal suffered ventricular fibrillation 
during 5 pg/kg/min prenalterol infusion, and one animal developed 
ventricular tachycardia during 3 pg/kg/min dobutamine infusion. 
Saline treated animals had no ventricular tachyarrhythmias. 
The duration of the hemodynamic effect was substantially longer 
after discontinuation of prenalterol than dobutamine, with 
hemodynamic half-lives (change in non-ischemic zone contractile 
force) of 3 hours and 1 . 7  min respectively. 
11. Chronic heart failure in patients 
Baseline hemodynamic measurements prior to drug administration 
confirmed severe heart failure in all patients (Table I, Figures 
11-16) .  Left ventricular ejection fraction ranged from 10-26% with 
a mean of 17+5%;  cardiac index ranged from 1 . 4  to 2.7 l/min/m 
with a mean of 1 .720 .4  l/min/m2; left ventricular stroke work 
index ranged from 12-28 g m/m2 with a mean of 1826 g m/m ; and 
left ventricular filling pressure ranged from 16-32 mm Hg (mean 
26+6 mm Hg). Elevated systemic arteriolar resistance (mean 
18725493 dyne s e  ~m'~) and pulmonary arteriolar resistance (mean 
3382 129  dyne s. cmm5 ) were also present. 
2 
2 
Peak hemodynamic effects after prenalterol administration a re  shown 
in Figures 11-16 and Table I. Significant increases in left 
ventricular ejection fraction (to 2 6 + 4 % ) ,  cardiac index ( t o  2 .4k0 .6  
l/min/m2) and left ventricular stroke work index (to 25 g * m / r n 2 )  
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TABLE I. C h a r a c t e r i s t i c s  o f  P a t i e n t s  and Response t o  P r e n a l t e r o l  
Hear t  Rate S y s t o l i c  A r t e r i a l  Mean A r t e r i a l  
(beats/min) P-essure (mnHg) Pressure (mmHg) 
P t  x Age Sex Diagnosis Base l ine  Maximum Base l ine  Maximum Easel i n e  Maximum 
1 63 M Ischemic 75 80 116 120 90 92 
2 53 F A l c o h o l i c  74 a3 110 130 94 98 
3 64 F Ischemic 39 106 135 140 84 91 
4 56 F I d i o p a t h i c  120 122 118 130 87 98 
5* 60 F Ischemic 110 102 74 
6 48 M I d i o p a t h i c  71 90 128 135 92 93 
7 64 M Ischemic 96 102 135 140 97 100 
8 5 5  M Ischemic 75 75 108 120 88 94 
9 70 M Ischemic 72 68 104 107 74 77 
Meanr SD 5 9 r  7 87 r 18 92 t 7 91 f 18 1 1 7 t  13 128+ 11 87 f 8 
P vs Base l ine  0.05 0.004 0.007 
*Pt X5 experienced v e n t r i c u l a r  tachycard ia  a f t e r  1 mg i n f u s i o n  and was excluded from f u r t h e r  a n a l y s i s .  
D i a s t o l i c  A r t e r i a l  LVEF LVSWI Cardiac Index 
Pressure (mnHg) ( X I  (gm.m/m2) (L/mi n/m2 ) 
P t l  Easel i n e  Maximum Easel i n e  Maximum Base l ine  Maximum Easel i n e  Maximum 
1 78 78 17 26 21 28 1.9 2.7 
** 22 21 1.8 1.8 2 86 a8 ** 
3 62 67 26 31 28 30 2.7 3.1 
4 71 85 20 21 12 17 1.8 1.9 
5 62 12 12 2.0 
6 78 75 18 29 27 40 2.0 3.2 
7 78 82 17 25 16 22 1.8 2.7 
a 75 76 10 21 17 2a 1.4 2.0 
9 60 65 12 26 12 15 1 .4  15. 
Mean f SD 72 t 9 77 2 a 17 r 5 26 t 4 !8 f 6 25 5 .a  i . g a . 4  2.3 -0.6-- 
* *Tcchn lca l l y  u n s a t i s f a c t o r y  rad ionuc l  i d e  card iac  b lood pool scan 
LVEF - L e f t  V e n t r i c u l a r  E j e c t i o n  F r a c t i o n  L V S W I  = L e f t  V e n t : i c u l a r  S t roke  Work Index 
P vs Base l ine  0.09 0.002 0. OOd 0.015 
Systemat ic A r t e r  i - Mean R i g h t  - 
LVFP PAP o l a r  Resistance A t r i a l  Pressure 
(mHg)  (mmHg) (dynes - ~ e c . c m - ~ )  (mnHg) 
P t  # Base l ine  Minimum Basel I n e  Minimum Sasel i n e  Minislim Basel i n e  Minimum 
1 31 25 54 41 10 NA 
2 2a 25 42 40 2229 2289 16 12 
3 16 18 34 36 1460 1280 10 10  
4 28 23 34 30 1786 2075 18 15 
5 26 34 1549 12 
6 20 11 31 22 1436 903 6 5 
7 32 30 51 40 21 33 141 3 18 12 
8 16 7 26 17  2802 2071 8 4 
9 32 29 45 40 1780 1692 20 18 
k a n  f SD 26 i 6 21 f 8 39 f 9 34 z 11 ,1872t493 1 6 7 4 r 5 0 2  13 f 5 11 f. 5 
P vs  Basel ine 0 .01  0.02 0.11 9.01 - 
LVFP * L e f t  V e n t r i c u l a r  F i l l i n g  Pressure - Mean Pulmonary A r t e r y  Pressure NA = Not A v a i l a b l e  
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occurred with significant decreases in left ventricular filling 
pressure (to 2128 mm Hg), pulmonary arteriolar resistance (to 
215285 dyn-~ecm-~) and mean right atrial pressure (to 11+5 mm Hg). 
Systemic arteriolar resistance declined (to 16742502 dyne S *  
without achieving significance (p>O.11). Heart rate increased 
significantly (from 87218 to 91218 beats/min) as did mean arterial 
pressure (from 87t8 to 92+7 mm Hg). 
Variable hemodynamic responses were noted (Table I, Figures 11-16) 
and no significant differences among peak effects at different 
doses were present. Correlation between response (as measured by 
Increase in LVEF) with several baseline parameters revealed that 
basal heart rate was inversely correlated with Increase in ejection 
fraction following prenalterol (r = -0.89, p<O.Ol, Figure 17). 
Holter monitor analysis demonstrated that two patients developed 
increased numbers of ectopic ventricular complexes during 
prenalterol administration and two other patients developed 
unsustained ventricular tachycardia. Both of the latter patients 
had ischemic cardiomyopathy treated with digoxin at the time of 
study without antiarrhythmic therapy. 
No subjective adverse effects were noted and no 
electrocardiographic evidence of worsening ischemia was seen. 
DISCUSSION 
The present studies demonstrate that intravenous prenalterol causes 
significant hemodynamic improvement in both acute and chronic low 
output states, and that its effects are comparable to those of 
dobutamine in a canine model of acute ischemic heart failure. 
Previous investigatlons of prenalterol indicate that its inotropic 
action is due to myocardial Bl-receptor stimulation [I, 51, 
although the drug binds non-selectively to other 8-receptors [5, 61 
and it possesses 8 -adrenergic antagonistic activity [6, 71. 
Isolated tissue preparation studies have demonstrated that 
prenalterol has less intrinsic 8-agonist effect than isoproterenol 
[5, 61. Thus, prenalterol could be classified as a partial 
0-agonist with relatively selective myocardial B1-stimulating 
2 
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properties and inherent 8-adrenergic antagonistic effect in some 
other tissues. It is of interest that prenalterol does not elevate 
myocardial adenylate cyclase levels [ 5 ] ,  as would be anticipated 
with catecholamines. This fact, in addition to its 
non-catecnolamine structure and its prolonged hemodynamic effect 
raises the possibility that prenalterol’s mechanism of action and 
route of metabolism may, in part, differ from those of 
catecholamine inotropic agents. 
Results from this study are in agreement with previous 
investigations of prenalterol in normal experimental animals [ 11 
and normal volunteers [2, 31, as well as patients with ventricular 
dysfunction [ 8, 91. Hemodynamic improvement appears to result from 
both inotropic stimulation and a reduction in left ventricular 
outflow resistance (afterload reduction). Although difficulties 
exist in distinguishing afterload reduction from inotropic 
stimulation in the intact subject, a predominant inotropic effect 
of prenalterol is suggested by [ l ]  its relatively selective 
B1-stimulating effect with B2-blocking activity consistent with 
myocardial ( B  ) stimulation but little or no peripheral arteriolar 
( B 2 )  stimulation and [2] an increase in mean systemic arterial 
pressure despite a decrease in systemic arteriolar resistance 
(Table I) in contrast to the decline in blood pressure or minimal 
blood pressure effect associated with vasodilators [ l o ] .  It is 
possible that the decrease in peripheral vascular resistance caused 
by prenalterol is in part reflexively mediated by baroreceptor 
stimulation due to blood pressure elevation. The net hemodynamic 
effect of prenalterol is a shift in the ventricular function curve 
upward and to the left (Figure 18) ,  as noted with other inotropic 
agents . 
1 
In addition to its positive inotropic and afterload reducing 
properties, prenalterol appears to possess a preload reducing 
(venodilating) effect, as evidenced by a reduction in left 
ventricular filling pressure (Figure 14) and a reduction in mean 
right atrial pressure (Figure 16) in patients with heart failure. 
Similar results have been reported following dobutamine 
administration [ l o ,  111. The failure of dobutamine and prenalterol 
to lower left ventricular end-diastolic pressure compared to saline 
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controls in the present animal investigation may be related to 
differences between the acute ischemic canine model of heart 
failure and the more chronic, stable left ventricular failure 
present in the patients studied. 
Also of interest is prenalterol’s ability to reduce elevated 
pulmonary vascular resistance in heart failure (Table I), similar 
to the effect of dobutamine as reported by Mikulic et al. 
This may be an additional contributing factor to the patients’ 
hemodynamic improvement. 
[ l o ] .  
In the canine model of acute ischemic heart failure prenalterol and 
dobutamine caused similar increases in LV dP/dt and non-ischemic 
zone contractile force and similar reductions in systemic vascular 
resistance. Differences existed, however, in prenalterol’s 
markedly longer duration of action and the greater increases in 
cardiac output, mean arterial pressure and pressure rate product 
associated with dobutamine. 
max 
Prenalterol’s longer duration of action represents a potential 
advantage over dobutamine if sustained inotropic effect after 
discontinuation of infusion is desirable, but it could be 
disadvantageous in the presence of an adverse reaction. The 
greater cardiac output associated with high doses of dobutamine may 
be an advantage relative to prenalterol, but it is primarily due to 
greater increases in heart rate and is associated with 
significantly greater increases in pressure rate product indicative 
of higher myocardial oxygen demand, a potentially deleterious 
effect in acute ischemia. A possible explanation for this 
difference in pressure rate product changes is the partial 
8-agonistic property of prenalterol, which may limit heart rate and 
blood pressure increases at higher doses. 
The extent of ischemic injury following prenalterol and dobutamine 
was not assessed in this animal study, but previous investigations 
with dobutamine indicate that it is not associated with increased 
infarct size in either experimental [ 1 2 ]  or clinical [ 1 3 ]  
myocardial infarction. Because prenalterol causes less blood 
pressure and heart rate increase than dobutamine, it is even less 
2 82 
likely to be associated with increased ischemic damage. 
The administration of both inotropic agents was associated with 
ventricular arrhythmias in the acute ischemic canine model and two 
prenalterol treated patients with ischemic cardiomyopathy developed 
ventricular tachycardia. While arrhythmias due to catheterization 
or Ischemia per se cannot be excluded, their occurrence during drug 
administration and the absence of sustained rhythm disturbances in 
saline control animals suggest a cause and effect relationship 
between dobutamine and prenalterol administration and ventricular 
arrhythmias. This finding i s  consistent with prior experience with 
adrenergic inotropic agents [ 1 4 ] .  Both prenalterol treated 
patients with ventricular tachycardia were chronically digitalized, 
raising the possibility that the combination of digoxin and 
adrenergic stimulation in the presence of severe ischemic heart 
disease may induce arrhythmias. 
The considerable variation in response to prenalterol and the lack 
of significant differences among peak hemodynamic responses to 
varying doses in the patient study may be related to the drug’s 
intrinsic 8-adrenergic blocking effect, which could inhibit further 
response at higher doses. This may also account for the lower 
plateau compared to dobutamine in dose-response curves noted in the 
animal study (Figures 5-7). The inverse correlation between 
baseline heart rate and increase in left ventricular ejection 
fraction with prenalterol (Figure 17) may also explain in part the 
variability of patient response, and suggests that increased 
resting sympathetic tone (as manifested by tachycardia) may llmit 
the response to further stimulation by adrenergic inotropic agents. 
In conclusion, intravenous prenalterol results in hemodynamic 
improvement in patients with severe chronic heart failure and in a 
canine model of an acute ischemic low output state. The drug’s 
hemodynamic effects are equivalent to those of dobutamine in the 
canine model except for prenalterol’s longer duration of action and 
greater increases in heart rate and blood pressure at high dose 
dobutamine, resulting in higher pressure rate product and cardiac 
output. The primary mechanisms of prenalterol s beneficial 
hemodynamic effect appear to be an increase in contractile force, 
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greater in non-ischemic than In severely ischemic tissue, and a 
reduction of systemic vascular resistance. Reductions in pulmonary 
vascular resistance and systemic venous pressure may also 
contribute to its beneficial effect. However, ventricular 
arrhythmias may be associated with prenalterol, as with other 
inotropic stimulants, and the drug should be administered with 
careful electrocardiographic monitoring. 
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